logo-loader
viewLexaGene Holdings Inc.

LexaGene says flagship product MiQLab being manufactured for commercial launch in September 2020

MiQLab is a fully automated genetic analyzer designed to deliver reference-quality data at the point-of-need in about an hour

Lexagene Holdings Inc. - LexaGene Holdings Inc says flagship product MiQLab is being manufactured for an anticipated commercial launch in September 2020
To start, the company anticipates offering three sets of chemistries, including a COVID-19 test

LexaGene Holdings Inc (CVE:LXG) (OTCQB:LXXGF) announced Monday that its flagship analyzer product MiQLab is being manufactured for an anticipated commercial launch by the end of September 2020.

MiQLab is a fully automated genetic analyzer designed to deliver reference-quality data at the point-of-need. The technology screens samples for up to 27 different targets at once -- looking for pathogens and/or antimicrobial resistance factors -- and returns results in approximately one hour. It is designed to be operated at the site of sample collection to avoid the delay associated with shipping and manually processing samples. 

READ: LexaGene says LX Analyzer is effective at detecting the presence and quantity of coronavirus in human samples

LexaGene said the technology can be used in multiple billion-dollar markets, including human and veterinary diagnostics as well as food safety testing.

“We started this company with a vision to create a technology that the world needs, particularly during these difficult times as we struggle to contain the spread of COVID-19,” LexaGene CEO Dr Jack Regan said in a statement.

“We have finished incorporating the feedback from beta testing and have begun manufacturing our commercial instrument, the MiQLab genetic analyzer. It is extremely gratifying to be so close to the start of selling this much-needed technology.”

WATCH: LexaGene prepares for commercialization of their newly named device MiQLab

MiQLab is open-access, which allows users to customize their tests easily. The company said comparable point-of-need instruments that allow for easy assembly and performance of highly multiplexed tests are not commercially available in a market valued at $20 billion. 

For example, scientists who have custom testing needs make up the open-access market, and they currently spend hours a day to manually perform PCR testing. These same individuals will now have the opportunity to save hours a day by having MiQLab automate the processing of their own tests, LexaGene noted.

“We are not only manufacturing the device, but also the associated consumables for our razor blade business model,” Regan said. “Our consumables include the single-use disposable cartridge for sample preparation as well as the PCR test chemistry, which MiQLab automates.” 

At volume manufacturing, LexaGene said it expects the costs for its consumables to be substantially lower than competing technologies, which will allow the company to maintain healthy profit margins even when selling into cost-sensitive markets.

Offering three sets of chemistries

To start, the company said it anticipates offering three sets of chemistries, namely, a COVID-19 test, a bacterial and antimicrobial panel for veterinary diagnostics that will screen for eight different pathogens (E. coli, Proteus, Klebsiella, Enterobacter, Pseudomonas, Staphylococcus, Streptococcus and Enterococcus) and 12 antibiotic resistance factors including methicillin and vancomycin resistance, and an open-access panel to facilitate customized genetic testing.

LexaGene has submitted a preliminary plan for COVID-19 testing to the US Food and Drug Administration and is still in conversations with the agency regarding the proposed studies for its technology. 

As is standard practice, until the FDA grants LexaGene’s instrument EUA for COVID-19 testing, all work using LexaGene instruments is classified as Research Use Only and cannot be used for human clinical diagnostics.

The company’s stock recently traded up by 16% to $0.83 a share in New York and rose by 15.3% to C$1.13 a share in Canada. 

--UPDATES stock price--

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

 

Quick facts: LexaGene Holdings Inc.

Price: 1.01 CAD

TSX-V:LXG
Market: TSX-V
Market Cap: $92.8 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of LexaGene Holdings Inc. named herein, including the promotion by the Company of LexaGene Holdings Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

LexaGene hires two salespeople to tackle diagnostic and vet market with new...

LexaGene (CVE: LXG-OTCQB: LXXGF) CEO Dr Jack Regan joined Steve Darling from Proactive Vancouver with news the company has made two key sales hires as they look to begin to roll out their genetic analyzers for rapid pathogen detection called MiQLab. Regan says they are hiring in the...

3 weeks, 2 days ago

3 min read